Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Hilton Hotels Corporation Common Stock (HLT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Hilton Hotels Corporation Common Stock — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Hilton Hotels Corporation Common Stock trades at $335.87 (market cap $76.37B). The key difference: Hilton Hotels Corporation Common Stock is the larger of the two by market cap, and Hilton Hotels Corporation Common Stock pays a 0.18% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | HLT | |
|---|---|---|
Market Cap | $39.89B | $76.37B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $350.22 |
52-Week Low | $278.09 | $256.75 |
Enterprise Value | $38.15B | $88.87B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Hilton Worldwide (HLT) trades at $335.48, down 0.64% on the day, with a bullish technical signal and strong earnings beat history. Revenue grew to $12.04B in 2025 with a net income margin of 12.56%, though valuation multiples appear elevated with a P/E of 51.22. Recent news highlights brand campaigns and property renovations, supporting positive sentiment.
Outlook remains favorable with analyst consensus price target of $342.11 implying modest upside. Risks include high debt levels and sensitivity to travel demand fluctuations. The stock offers growth exposure to hospitality recovery but requires monitoring of leverage and macroeconomic trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →
